{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=3",
    "query": {
      "intervention": "Placebo- C",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 1832,
    "total_pages": 184,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T18:02:12.043Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05021835",
      "title": "ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cardiovascular Risk",
        "Chronic Kidney Disease",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "Ziltivekimab B",
          "type": "DRUG"
        },
        {
          "name": "Ziltivekimab C",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Ziltivekimab B)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Ziltivekimab C)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6385,
      "start_date": "2021-08-30",
      "completion_date": "2026-06-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-19T18:02:12.043Z",
      "location_count": 181,
      "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Glendale, Arizona + 140 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05021835"
    },
    {
      "nct_id": "NCT01672359",
      "title": "Evaluating Whole Foods Supplementation on Cognition",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sub-optimal Cognitive Function",
        "Sub-optimal Immune Function"
      ],
      "interventions": [
        {
          "name": "Ginkgo Synergy® and Choline",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "OPC Synergy® and Catalyn",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2011-05",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2014-08-06",
      "last_synced_at": "2026-10-19T18:02:12.043Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01672359"
    },
    {
      "nct_id": "NCT00700479",
      "title": "Studies on Aldosterone and Vascular Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "aldosterone",
          "type": "DRUG"
        },
        {
          "name": "low or high sodium diet",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2006-01",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2008-06-18",
      "last_synced_at": "2026-10-19T18:02:12.043Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00700479"
    },
    {
      "nct_id": "NCT01590446",
      "title": "A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Achondroplasia"
      ],
      "interventions": [
        {
          "name": "BMN 111",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioMarin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "22 Years to 45 Years · Male only"
      },
      "enrollment_count": 74,
      "start_date": "2012-02",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2012-06-11",
      "last_synced_at": "2026-10-19T18:02:12.043Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01590446"
    },
    {
      "nct_id": "NCT06026397",
      "title": "A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chemotherapy-induced Diarrhea"
      ],
      "interventions": [
        {
          "name": "SK10",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Guangzhou Zhiyi Biotechnology Co., Ltd.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2023-08-01",
      "completion_date": "2024-02-11",
      "has_results": false,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-10-19T18:02:12.043Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06026397"
    },
    {
      "nct_id": "NCT03565068",
      "title": "A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "MK-8189",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Background AAP Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 75,
      "start_date": "2018-06-20",
      "completion_date": "2020-04-03",
      "has_results": true,
      "last_update_posted_date": "2021-03-29",
      "last_synced_at": "2026-10-19T18:02:12.043Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03565068"
    },
    {
      "nct_id": "NCT04478708",
      "title": "Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "maridebart cafraglutide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 110,
      "start_date": "2020-08-07",
      "completion_date": "2022-11-18",
      "has_results": true,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-10-19T18:02:12.043Z",
      "location_count": 3,
      "location_summary": "Anaheim, California • Tustin, California • Miami, Florida",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04478708"
    },
    {
      "nct_id": "NCT02530996",
      "title": "Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Rheumatologic Disease"
      ],
      "interventions": [
        {
          "name": "BH4",
          "type": "DRUG"
        },
        {
          "name": "Vasculopathy assessment",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 12,
      "start_date": "2016-01-01",
      "completion_date": "2019-12-31",
      "has_results": true,
      "last_update_posted_date": "2021-04-05",
      "last_synced_at": "2026-10-19T18:02:12.043Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02530996"
    },
    {
      "nct_id": "NCT00711386",
      "title": "GSK706769 Repeat Dose Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK706769",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 40,
      "start_date": "2008-05-16",
      "completion_date": "2008-09-12",
      "has_results": false,
      "last_update_posted_date": "2017-08-03",
      "last_synced_at": "2026-10-19T18:02:12.043Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00711386"
    },
    {
      "nct_id": "NCT07220785",
      "title": "Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Lipodystrophy"
      ],
      "interventions": [
        {
          "name": "Mibavademab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2026-03-13",
      "completion_date": "2028-09-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-19T18:02:12.043Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Dallas, Texas",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220785"
    }
  ]
}